|
[1]MOLODECKY NA,SOON IS,RABI DM,et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012,142(1):46-54.e42;quiz e30．
|
|
[2]IIDA T,YOKOYAMA Y,WAGATSUMA K,et al.Impact of autophagy of innate immune cells on inflammatory bowel disease[J].Cells,2018,8(1):7．
|
|
[3]VAVRICKA SR,SCHOEPFER A,SCHARL M,et al.Extraintestinal manifestations of inflammatory bowel disease[J].Inflamm Bowel Dis,2015,21(8):1982-1992．
|
|
[4]PITCHUMONI CS,RUBIN A,DAS K.Pancreatitis in inflammatory bowel diseases[J].J Clin Gastroenterol,2010,44(4):246-253．
|
|
[5]HEIKIUS B,NIEMELS,LEHTOLA J,et al.Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease[J].Am J Gastroenterol,1999,94(4):1062-1069．
|
|
[6]CHEN YT,SU JS,TSENG CW,et al.Inflammatory bowel disease on the risk of acute pancreatitis:A population-based cohort study[J].J Gastroenterol Hepatol,2016,31(4):782-787．
|
|
[7]FOUSEKIS FS,KATSANOS KH,THEOPISTOS VI,et al.Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases:A referral center study[J].BMC Gastroenterol,2019,19(1):48．
|
|
[8]GIZARD E,FORD AC,BRONOWICKI JP,et al.Systematic review:The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2014,40(1):3-15．
|
|
[9]ZHANG FM,XU CF,SHAN GD,et al.Is gallstone disease associated with inflammatory bowel diseases?A meta-analysis[J].J Dig Dis,2015,16(11):634-641．
|
|
[10]JEONG YH,KIM KO,LEE HC,et al.Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population[J].Medicine(Baltimore),2017,96(31):e7653．
|
|
[11]CHEN CH,LIN CL,KAO CH.Association between inflammatory bowel disease and Cholelithiasis:A nationwide population-based cohort study[J].Int J Environ Res Public Health,2018,15(3):513．
|
|
[12]MAURER P,HAAG K,ROTH M,et al.No evidence for abnormal gallbladder emptying in Crohn's disease[J].Hepatogastroenterology,1996,43(10):807-812．
|
|
[13]PARENTE F,PASTORE L,BARGIGGIA S,et al.Incidence and risk factors for gallstones in patients with inflammatory bowel disease:A large case-control study[J].Hepatology,2007,45(5):1267-1274．
|
|
[14]TEICH N,MOHL W,BOKEMEYER B,et al.Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases-a prospective study on incidence and severity[J].J Crohns Colitis,2016,10(1):61-68．
|
|
[15]LEDDER O,LEMBERG DA,DAY AS.Thiopurine-induced pancreatitis in inflammatory bowel diseases[J].Expert Rev Gastroenterol Hepatol,2015,9(4):399-403．
|
|
[16]BERMEJO F,LOPEZ-SANROMAN A,TAXONERA C,et al.A-cute pancreatitis in inflammatory bowel disease,with special reference to azathioprine-induced pancreatitis[J].Aliment Pharmacol Ther,2008,28(5):623-628．
|
|
[17]WILSON A,JANSEN LE,ROSE RV,et al.HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2018,47(5):615-620．
|
|
[18]RIBALDONE DG,ADRIANI A,CAVIGLIA GP,et al.Correlation between thiopurine S-methyltransferase genotype and adverse events in inflammatory bowel disease patients[J].Medicina(Kaunas),2019,55(8):441．
|
|
[19]GARAU P,ORENSTEIN SR,NEIGUT DA,et al.Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis[J].J Pediatr Gastroenterol Nutr,1994,18(4):481-485．
|
|
[20]RANSFORD RA,LANGMAN MJ.Sulphasalazine and mesalazine:Serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines[J].Gut,2002,51(4):536-539．
|
|
[21]FERNNDEZ J,SALA M,PANS J,et al.Acute pancreatitis after long-term 5-aminosalicylic acid therapy[J].Am J Gastroenterol,1997,92(12):2302-2303．
|
|
[22]FAINTUCH J,MOTT CB,MACHADO MC.Pancreatitis and pancreatic necrosis during sulfasalazine therapy[J].Int Surg,1985,70(3):271-272．
|
|
[23]SRINATH AI,GUPTA N,HUSAIN SZ.Probing the association of pancreatitis in inflammatory bowel disease[J].Inflamm Bowel Dis,2016,22(2):465-475．
|
|
[24]MECZKER，MIKA,GEDE N,et al.Retrospective matched-cohort analysis of acute pancreatitis induced by 5-aminosalicylic acid-derived drugs[J].Pancreas,2019,48(4):488-495．
|
|
[25]WERLANG ME,LEWIS MD,BARTEL MJ.Tumor necrosis factor alpha inhibitor-induced acute pancreatitis[J].ACG Case Rep J,2017,4:e103．
|
|
[26]PICARDO S,SO K,VENUGOPAL K,et al.Vedolizumab-induced acute pancreatitis:The first reported clinical case[J].BMJ Case Rep,2018,2018:bcr2017222554．
|
|
[27]STOBAUGH DJ,DEEPAK P.Effect of tumor necrosis factor-αinhibitors on drug-induced pancreatitis in inflammatory bowel disease[J].Ann Pharmacother,2014,48(10):1282-1287．
|
|
[28] NITSCHE C,MAERTIN S,SCHEIBER J,et al.Drug-induced pancreatitis[J].Curr Gastroenterol Rep,2012,14(2):131-138．
|
|
[29]FORSMARK CE,BAILLIE J,AGA Institute Clinical Practice and Economics Committee,et al.AGA Institute technical review on acute pancreatitis[J].Gastroenterology,2007,132(5):2022-2044．
|
|
[30] SADR-AZODI O,MATTSSON F,BEXLIUS TS,et al.Association of oral glucocorticoid use with an increased risk of acute pancreatitis:A population-based nested case-control study[J].JAMA Intern Med,2013,173(6):444-449．
|
|
[31]LEGGE DA,HOFFMAN HN 2nd,CARLSON HC.Pancreatitis as a complication of regional enteritis of the duodenum[J].Gastroenterology,1971,61(6):834-837．
|
|
[32]GSCHWANTLER M,KOGELBAUER G,KLOSE W,et al.The pancreas as a site of granulomatous inflammation in Crohn's disease[J].Gastroenterology,1995,108(4):1246-1249．
|
|
[33]MELTZER SJ,KORELITZ BI.Pancreatitis and duodenopancreatic reflux in Crohn's disease.Case report and review of the literature[J].J Clin Gastroenterol,1988,10(5):555-558．
|
|
[34]FOUSEKIS FS,THEOPISTOS VI,KATSANOS KH,et al.Pancreatic involvement in inflammatory bowel disease:A review[J].J Clin Med Res,2018,10(10):743-751．
|
|
[35]GOLDIN E,LIBSON E,WENGROWER D,et al.Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis:Treatment by endoscopic insertion of a biliary stent[J].Int Surg,1990,75(1):58-60．
|
|
[36]SAID K,GLAUMANN H,BERGQUIST A.Gallbladder disease in patients with primary sclerosing cholangitis[J].J Hepatol,2008,48(4):598-605．
|
|
[37]NITSCHE C,MAERTIN S,SCHEIBER J,et al.Drug-induced pancreatitis[J].Curr Gastroenterol Rep,2012,14(2):131-138．
|
|
[38]DONG LH,LIU ZM,WANG SJ,et al.Corticosteroid therapy for severe acute pancreatitis:A meta-analysis of randomized,controlled trials[J].Int J Clin Exp Pathol,2015,8(7):7654-7660．
|
|
[39]TRIANTAFILLIDIS JK,CHERACAKIS P,HERETI IA,et al.Acute idiopathic pancreatitis complicating active Crohn's disease:Favorable response to infliximab treatment[J].Am J Gastroenterol,2000,95(11):3334-3336．
|
|
[40]KHANDELWAL A,INOUE D,TAKAHASHI N.Autoimmune pancreatitis:An update[J].Abdom Radiol(NY),2020,45(5):1359-1370．
|
|
[41]IIDA T,WAGATSUMA K,HIRAYAMA D,et al.The etiology of pancreatic manifestations in patients with inflammatory bowel disease[J].J Clin Med,2019,8(7):916．
|
|
[42]TSEN A,ALISHAHI Y,ROSENKRANZ L.Autoimmune pancreatitis and inflammatory bowel disease:An updated review[J].J Clin Gastroenterol,2017,51(3):208-214．
|
|
[43]UEKI T,KAWAMOTO K,OTSUKA Y,et al.Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease[J].Pancreas,2015,44(3):434-440．
|
|
[44]LORENZO D,MAIRE F,STEFANESCU C,et al.Features of autoimmune pancreatitis associated with inflammatory bowel diseases[J].Clin Gastroenterol Hepatol,2018,16(1):59-67．
|
|
[45]RAVI K,CHARI ST,VEGE SS,et al.Inflammatory bowel disease in the setting of autoimmune pancreatitis[J].Inflamm Bowel Dis,2009,15(9):1326-1330．
|
|
[46]SHIMOSEGAWA T,CHARI ST,FRULLONI L,et al.International consensus diagnostic criteria for autoimmune pancreatitis:Guidelines of the International Association of Pancreatology[J].Pancreas,2011,40(3):352-358．
|
|
[47]CONWELL DL,LEE LS,YADAV D,et al.American pancreatic association practice guidelines in chronic pancreatitis:Evidence-based report on diagnostic guidelines[J].Pancreas,2014,43(8):1143-1162．
|
|
[48]BARTHET M,HASTIER P,BERNARD JP,et al.Chronic pancreatitis and inflammatory bowel disease:True or coincidental association?[J].Am J Gastroenterol,1999,94(8):2141-2148．
|
|
[49]CHEN YL,HSU CW,CHENG CC,et al.Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis:A nationwide population-based cohort study[J].Curr Med Res Opin,2017,33(6):1077-1082．
|
|
[50]ZAMBONI GA,AMBROSETTI MC,PEZZULLO M,et al.Optimum imaging of chronic pancreatitis[J].Abdom Radiol(NY),2020,45(5):1410-1419．
|
|
[51]SINGH VK,YADAV D,GARG PK.Diagnosis and management of chronic pancreatitis:A review[J].JAMA,2019,322(24):2422-2434．
|
|
[52]SHARZEHI K.Management of pancreatic duct stones[J].Curr Gastroenterol Rep,2019,21(11):63．
|
|
[53]CAPURSO G,TRAINI M,PICIUCCHI M,et al.Exocrine pancreatic insufficiency:Prevalence,diagnosis,and management[J].Clin Exp Gastroenterol,2019,12:129-139．
|
|
[54]MACONI G,DOMINICI R,MOLTENI M,et al.Prevalence of pancreatic insufficiency in inflammatory bowel diseases.Assessment by fecal elastase-1[J].Dig Dis Sci,2008,53(1):262-270．
|
|
[55]ANGELINI G,CAVALLINI G,BOVO P,et al.Pancreatic function in chronic inflammatory bowel disease[J].Int J Pancreatol,1988,3(2-3):185-193．
|
|
[56]HEIKIUS B,NIEMELS,LEHTOLA J,et al.Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease[J].Scand J Gastroenterol,1996,31(5):517-523．
|
|
[57]SINGH VK,HAUPT ME,GELLER DE,et al.Less common etiologies of exocrine pancreatic insufficiency[J].World J Gastroenterol,2017,23(39):7059-7076．
|
|
[58]de la IGLESIA-GARCA D,HUANG W,SZATMARY P,et al.Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis:Systematic review and meta-analysis[J].Gut,2017,66(8):1354-1355．
|
|
[59]ANANTHAKRISHNAN AN,CAGAN A,GAINER VS,et al.Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease[J].J Crohns Colitis,2014,8(9):956-963．
|
|
[60]JUNG YS,HAN M,PARK S,et al.Cancer risk in the early stages of inflammatory bowel disease in Korean patients:A nationwide population-based study[J].J Crohns Colitis,2017,11(8):954-962．
|
|
[61]CHAMS S,BADRAN R,SAYEGH SE,et al.Inflammatory bowel disease:Looking beyond the tract[J].Int J Immunopathol Pharmacol,2019,33:2058738419866567．
|
|
[62]GARRIDO GMEZ E,LOPEZ SAN ROMN A,BERMEJO SANJOSF.Idiopathic pancreatitis in inflammatory bowel disease[J].JCrohns Colitis,2008,2(3):237-240．
|
|
[63]MOOLSINTONG P,LOFTUS EV Jr,CHARI ST,et al.Acute pancreatitis in patients with Crohn's disease:Clinical features and outcomes[J].Inflamm Bowel Dis,2005,11(12):1080-1084．
|
|
[64]GARCIA GARCIA DE PAREDES A,RODRIGUEZ de SANTIAGO E,RODRIGUEZ-ESCAJA C,et al.Idiopathic acute pancreatitis in patients with inflammatory bowel disease:A multicenter cohort study[J].Pancreatology,2020,20(3):331-337．
|
|
[65]BROIDE E,DOTAN I,WEISS B,et al.Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients[J].J Pediatr Gastroenterol Nutr,2011,52(6):714-717．
|
|
[66]van DIJK SM,HALLENSLEBEN N,van SANTVOORT HC,et al.Acute pancreatitis:Recent advances through randomised trials[J].Gut,2017,66(11):2024-2032．
|
|
[67] HEIKIUS B,NIEMELS,LEHTOLA J,et al.Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease[J].Am J Gastroenterol,1999,94(4):1062-1069．
|
|
[68]BOKEMEYER B.Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn's disease and ulcerative colitis[J].Z Gastroenterol,2002,40(1):5-10．
|
|
[69]TROMM A,HLTMANN B,HPPE D,et al.Hyperamylasemia,hyperlipasemia and acute pancreatitis in chronic inflammatory bowel diseases[J].Leber Magen Darm,1991,21(1):15-16,19-22．
|
|
[70]TODA N,AKAHANE M,KIRYU S,et al.Pancreas duct abnormalities in patients with ulcerative colitis:A magnetic resonance pancreatography study[J].Inflamm Bowel Dis,2005,11(10):903-908．
|
|
[71]BARTHET M,LESAVRE N,DESPLATS S,et al.Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease[J].Pancreatology,2006,6(5):464-471.
|
DownLoad: